ISSN: 1859 - 2872
Evaluation of the expression of immunohistochemistry in hepatocellular carcinoma
Main Article Content
Keywords
Abstract
Objective: To study the expression of HepPar-1, Arginase-1, Glypican-3, CK7, CK19 in primary liver carcinoma. Subject and method: A cross-sectional study based on 82 cases of primary liver cancer at 108 Military Central Hospital from 01/2018 to 04/2020. Result: The sensitivities of HepPar-1, Arginase-1 and Glypican-3 were 67.4%, 83.7% and 60.5%, respectively. The specificity of HepPar-1, Arginase-1 and Glypican-3 were 92.3%, 97.4% and 100%, respectively. The combination of Arginase-1 and HepPar-1 or Glypican-3 yielded a high sensitivity of 87.9% and 93.9%, respectively. Conclusion: Arginase is a more sensitive marker than HepPar-1 and Glypican-3. The specificity of Glypican-3 was 100%. These 3 markers are recommended in the distinction of hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Article Details
References
2. Tiền Thanh Liêm, Bùi Huỳnh Quang Minh, Lê Minh Huy, Hứa Thị Ngọc Hà (2019) Mối liên quan giữa thời gian sống còn và biểu hiện, đồng biểu hiện của các dấu ấn tế bào gốc ung thư với đặc điểm giải phẫu bệnh của ung thư tế bào gan. Tạp chí Y học Thành Phố Hồ Chí Minh 23(5), tr. 185-195.
3. 704-viet-nam-fact-sheets.pdf. Accessed January 18, 2021. https://gco.iarc.fr/today/data/factsheets/ populations/704-viet-nam-fact-sheets.pdf.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424. doi:10.3322/caac. 21492.
5. Fujikura K, Yamasaki T, Otani K, et al (2016) BSEP and MDR3: Useful immunohistochemical markers to discriminate hepatocellular carcinomas from intrahepatic cholangiocarcinomas and hepatoid carcinomas. Am J Surg Patho 40(5): 689-696. doi: 10.1097/PAS.0000000000000585
6. Fujiwara M, Kwok S, Yano H, Pai RK (2012) Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol 120(4): 230-237. doi: 10.1002/cncy.21190.
7. Koh KC, Lee H, Choi MS et al (2005) Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 189(1): 120-125. doi: 10.1016/j.amjsurg. 2004.03.018.
8. Ryu HS, Lee K, Shin E et al (2012) Comparative analysis of immunohistochemical markers for differential diagnosis of hepatocelluar carcinoma and cholangiocarcinoma. Tumori J 98(4): 478-484. doi: 10.1177/0300891612098004135.
9. Timek DT, Shi J, Liu H, Lin F (2012) Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol 138(2): 203-210. doi: 10.1309/AJCPK1ZC9WNHCCMU.
10. Yan BC, Gong C, Song J, et al (2010) Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 34(8): 1147-1154. doi: 10.1097/PAS.0b013e 3181e5dffa.
Article Sidebar
